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Abstract 
In the post-genomic era, an idea of how similar the genomes of different species 
actually are is on the horizon. Less than 10 years ago, the human genome was 
estimated to encode 100000 genes. That was an overestimation, as the real number of 
human genes is 20000-25000. Most genes are expressed as proteins. The 3D structure 
of a protein is more conserved than its sequence, and therefore the structural context 
of protein and gene evolution must not be forgotten. By its structure, the protein can 
propagate its function. In the early 90’s the estimated number of different protein 
structure classes, so called folds, was predicted to be about 10000. Today there are 
slightly above 1000 folds and the discovery of new folds has leveled off, despite an 
increase in the number of protein structures that have been solved over the last few 
years. Indeed, some folds are used for more than one function, and found in various 
functional contexts. Then, if the many components are so similar, how is the 
biological species divergence from same component genomes achieved? One way to 
study biological diversity is by dividing it into its smaller components, e.g. by 
studying protein or gene family evolution. Here the evolution and regulation of the 
aromatic amino acid hydroxylase (AAAHs) have been under examination. This gene 
family encodes the proteins phenylalanine hydroxylase (PAH), tyrosine hydroxylase 
(TH), and tryptophan hydroxylase (TPH). These enzymes are highly physiologically 
important. PAH, expressed in liver, regulates the homeostasis of L-Phe by 
hydroxylating it into L-Tyr. TH, expressed in the central nervous system, 
hydroxylates L-Tyr into L-Dopa. L-Dopa is part of two important pathways i) 
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melanogenesis and ii) dopamine production. In humans, dysfunctions in PAH that 
cause elevated L-Phe concentration can result in phenylketonuria (PKU). Untreated 
PKU results in neurological damage. TPH produces a precursor of serotonin from L-
Trp. The end products of these enzymes are neurotransmitters and hormones with 
increasingly important functions, from e.g. amoeba to nematode to man. As PAH has 
evolved in mammals its regulation has become increasingly sophisticated, e.g. 
homotropic positive cooperativity that shifts the conformational equilibrium from 
dimeric to tetrameric is seen in the mammalian lineage. Nematode PAH is devoid of 
positive cooperativity, but resembles the tetrameric high-affinity and high-activity 
mammalian PAH. TH and TPH are always tetrameric and not allosterically regulated. 
Each AAAH subunit has a regulatory domain, a catalytic domain, and an 
oligomerization domain. The promotion of positive cooperativity in PAH has been 
investigated by comparing mammalian PAH to nematode PAH. The low-affinity and 
low-activity dimer as well as the high-affinity and high-activity tetramer of PAH 
were modeled. Sequence analysis on a nematode sequence cluster and a mammalian 
sequence cluster identified sites with high probability of being involved in functional 
divergence, e.g. change in regulation. Residue specific electrostatic interaction 
energies were calculated for all ionizible residues in the models. In general, we note 
important differences in the substrate binding pocket that aids to explain why the 
active site in nematode PAH is less dynamic than in mammalian PAH. Our results 
suggest a pathway for the positive cooperativity from one active site to another, 
involving various predicted hinge regions from human PAH, where we find the 
nematode PAH more rigid.  
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The regulatory domain in PAH is part of the ACT domain family. The ACT domains 
are frequently found regulating metabolic enzymes in an allosteric manner. The 
allosteric effector is often an amino acid that binds to an interface formed by two 
ACT domains. No contacts are formed between two ACT domains and the 
stoichiometry of binding is 1:1 for L-Phe in PAH. Therefore the allosteric effect must 
originate in the active site when the substrate binds. An alternative pathway for 
aromatic amino acid biosynthesis is present in e.g. plants and bacteria. This pathway 
has an L-Phe binding ACT domain, which is homologous to the ACT domain in 
AAAH. The L-Phe binding motif in this domain is also conserved in PAH. A 
comparative structural analysis of this area shows why L-Phe may not bind in the 
AAAH regulatory domain and also indicates why it has remained.  
The ACT domain has an abundant fold, a superfold. A structural approach was used 
to identify more potential ACT domains to gain further insights to the functional 
properties that this domain could perform in general, and in PAH in particular. Here 
we note e.g. two interesting potential domain families that could be homologous to 
the ACT domain, namely the GlnB-like domains and heavy metal binding domains.    
The phylogeny of the AAAH family has not been resolved earlier given the lack of a 
suitable outgroup. As more genome sequences became available, we identified an 
outgroup candidate and had it experimentally characterized. The phylogeny was 
resolved, the ancestral function determined, and by comparing the chromosomal gene 
locations the order of events in AAAH evolution was envisioned. 
 8 
List of publications 
Siltberg-Liberles, J., Steen, I. H., Svebak, R. M. & Martinez, A. (2008), “The phylogeny of 
the aromatic amino acid hydroxylases revisited by characterizing phenylalanine 
hydroxylase from Dictyostelium discoideum.”, GENE,  
doi:10.1016/j.gene.2008.09.005. In press  
Siltberg-Liberles, J. & Martinez, A. (2008), “Structural determinants of the regulatory 
properties in phenylalanine hydroxylase,” Manuscript. To be submitted. 
Liberles, J. S.*, Thorolfsson, M, & Martinez, A. (2005): “Allosteric mechanisms in ACT 
domain containing enzymes involved in amino acid metabolism.”, Amino Acids, 
28:1-12. 
Siltberg-Liberles, J. & Martinez, A. (2008): “Searching distant homologs of the regulatory 
ACT domain in phenylalanine hydroxylase.”, Amino Acids, doi:10.1007/s00726-
008-0057.2. In press 
* S as is Siltberg 
 
 
 9 
Contents 
ABBREVIATIONS………………………………………………………………13 
 
1. GENERAL INTRODUCTION……………………………………….15 
 
1.1.   EVOLUTION……………………………………………………….15 
1.1.1.    EVOLUTION OF DIFFERENT LIFE FORMS…………………………...15 
1.1.2.    PROTEINS AND THEIR EVOLUTION……………………………...….17 
1.1.3.    GENE DUPLICATION –  
   A DRIVING FORCE FOR NEW PROTEIN FUNCTIONS………..………. 21 
 
1.2.  HOMOLOGY…...………………..………………………………….23 
1.2.1.   ORTHOLOGS AND PARALOGS…………..…………...………………24 
1.2.2.    PROTEIN STRUCTURE COMPARISONS……………..……..…………25 
1.2.3.    PROTEIN FOLD DISTRIBUTION……………..……..………………...26 
1.2.4.    MULTIDOMAIN PROTEINS……...…………………………………...27 
1.2.5.     PROTEIN DOMAINS AND THEIR ORGANIZATION IN DATABASES…...28 
1.2.6.     FUNCTIONAL DIVERGENCE ON A SEQUENCE LEVEL…….………....30 
 
1.3.  MARGINALLY STABLE PROTEINS……….….………………….…..33 
1.3.1.     PROTEINS ARE MARGINALLY STABLE….....………………………...33 
1.3.2.     ALLOSTERY…………..……….………...…………………………...34 
 
1.4.  PHENYLALANINE HYDROXYLASE AND ITS HOMOLOGS …………...37 
 10 
1.4.1.     DOMAIN COMPOSITION……………..………………………………38 
1.4.2.     THE CATALYZED REACTION……………..………….………………42 
1.4.3.     THE PKU PHENOTYPE………………………..……………………..42 
1.4.4.     PAH REGULATION……………….…………………..……………...44 
 
2. METHODS AND THEORETICAL CONSIDERATIONS …..…….47 
 
2.1.   PROTEIN SEQUENCE ALIGNMENTS…………………………..........47 
2.1.2.    SEQUENCE ALIGNMENT…………………………………………..…47 
2.1.2.    STRUCTURAL ALIGNMENT……………………………………..……48 
 
2.2.   TREE BUILDING…….……….………..…………………………...50 
2.2.1.    DISTANCE METHODS….………..……………………………………50 
2.2.2.     DISCRETE METHODS ...…………....……………………………..….51 
 
2.3.   MODELS OF EVOLUTION……………….…………………………53 
 
2.4.   MODELING PROTEIN STRUCTURE……….………………………..55 
2.4.1.     HOMOLOGY MODELING…...…….………………..………………...56 
 
2.5.   DIVERGE ANALYSIS – PREDICTION OF SITES INVOLVED IN  
                       FUNCTIONAL CHANGE……………………………………………..59 
 
 11 
2.6.   ELECTROSTATIC INTERACTION ENERGIES…………….…………61 
 
3. AIMS……………...……………………………………………………62 
 
3.1.   THE EVOLUTION OF THE AAAHS………………………...………62 
 
3.2.   THE FUNCTION OF THE REGULATORY DOMAIN IN PAH……….....62 
 
4. CONTRIBUTIONS……………………………………………………65  
 
4.1.  LIST OF PAPERS………………………..…………………………..65 
4.1.1.  RESIDUE DENOMINATION…………………………………………….66 
 
4.2.   PAPER I: THE PHYLOGENY OF THE AROMATIC AMINO ACID 
           HYDROXYLASES…………………………….……………………..66      
 
4.3.   PAPER II: STRUCTURAL DETERMINANTS OF THE REGULATORY  
                        PROPERTIES IN PHENYLALANINE HYDROXYLASE..........................69 
 
 4.4.   PAPER III: THE ARCHETYPICAL ACT DOMAIN………………......72 
 
4.5.   PAPER IV: DISTANT HOMOLOGS OF THE ACT DOMAIN…….…...73 
 
 12 
5. GENERAL DISCUSSION……………………………...……….….....75 
 
6. CONCLUSION AND FUTURE DIRECTIONS….….….…………...81 
 
6.1.   CONCLUSIONS…………………………………………………….81 
 
6.2.   FUTURE DIRECTIONS……………………………………………...83 
 
7. REFERENCES………………………………………………………...86 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 13 
Abbreviations 
AAAH Aromatic Amino Acid Hydroxylase 
AIC   Akaike statistical test 
BH4     Tetrahydrobiopterin 
BLOSUM BLOck SUbstitution Matrices 
CE Combinatorial Extension 
DH4 Tetrahydrodictyopterin 
DictyoPAH Dictyostelium discoideum PAH 
FATCAT Flexible structure AlignmenT by Chaining Aligned fragment pairs 
allowing Twists 
h Hill coefficient 
IARS Intrinsic Auto Regulatory Sequence 
JTT Jones, Taylor, and Thornton 
MCMC Markov Chain Monte Carlo 
ML Maximum Likelihood 
MUSTANG  MUltiple STructural AligNment AlGorithm 
NJ Neighbor Joining 
PAH PhenylAlanine Hydroxylase 
PAM Point Accepted Mutations 
PDB Protein Data Bank 
PKA cAMP dependent Protein Kinase A 
PKU PhenylKetonUria 
P-protein bifunctional chorismate-prephenate dehydrogenase 
RMSD Root Mean Square Deviation 
SSAP Sequential Structure Alignment Program 
 14 
TH Tyrosine Hydroxylase 
TPH  TryPtophan Hydroxylase 
UPGMA Unweighted Pair Group Method with Arithmetic Mean 
3PGDH D-3-PhosphoGlycerate DeHydrogenase 
 
 
 
 
 
 
 
 
 
 
 
 
 15 
 
 
 
1. General introduction 
1.1. Evolution  
The Earth is about 4.6 billion years old. The first forms of life appeared about 
0.8 billion years later (Mojzsis et al. 1996; Holland 1997). Since then Nature has 
created an enormous biological diversity. The essence in this biological diversity 
originates in DNA. DNA carries all the essential information for a specific phenotype 
of a species in the genome. This information is carried on to the species offspring. 
However, genomes are always subjected to change and this brings on the evolution of 
new traits and, eventually, new species. Following is a brief introduction to how 
different life forms may have arisen and how that has affected e.g. the evolution of 
human kind.  
1.1.1. Evolution of different life forms 
Prokaryotes (Eubacteria and Archeabacteria) represent the first forms of life. 
Unicellular eukaryotes, also known as protozans, probably emerged from prokaryotic 
ancestry about 1.6 - 2.1 billion years ago (Knoll 1992), while multicellular 
eukaryotes, also known as metazoans (animals) and metaphytes (plants), originated 
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about 0.6 billion years ago. The period leading from unicellular to multicellular 
eukaryotes is often referred to as the Cambrian explosion, when extensive radiation 
took place (Lundin 1999). Many explanations have been put forward to account for 
this transition such as an increase in oxygen concentration in the atmosphere 
surrounding the Earth (Canfield and Teske 1996). As anaerobic metabolism has low 
energy yield it could only support low biomass, making aerobic metabolism a 
requirement for increasing biomass as seen in multicellular eukaryotes (Fenchel and 
Finlay 1994). Another explanation for the extensive radiation is cropping as a 
feedback cycle, involving the diversification of prey, giving rise to the diversification 
of predators. Such a scenario could make the rise of exoskeleton a potentially 
important event (Stanley 1973). Now in the post-genomic era we are starting to see 
the genomic effects of the burst in evolution taking place in the Cambrian era and, 
regardless of how and why this explosion took place, there were extensive gene 
duplications and domain rearrangements during that period, separating protozans 
from metazoans (Ekman et al. 2007). Another burst of radiation coupled to two 
rounds of whole genome duplication occurred during the chordate-vertebrate 
transition (McLysaght et al. 2002). These events are marked in Figure 1, which 
contains the species relevant to comprehend this thesis. The branches where 
duplication events and morphological innovation have taken place are marked. How 
gene duplications affect a genome are discussed below, but first a brief introduction 
to protein evolution.  
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Figure 1. A simplified tree of life, representing the species and major gene 
duplication events discussed in this thesis.  
 
1.1.2. Proteins and their evolution 
Proteins are expressed and encoded by the genes in a species DNA. The 
protein alphabet consists of 20 amino acids. The amino acids have different 
physicochemical characteristics and are often divided into clusters given these. For an 
example of the complexity in these clusters see Figure 2.  
As a consequence of their physicochemical characters the different amino 
acids have different propensities to form secondary structure elements. The two major 
secondary structure motifs are the -helix and the -sheet (Figure 3).  
Given the properties of the different amino acids and their succession in a 
protein sequence, the protein can rapidly fold into a distinct, thermodynamically 
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stable structure. One intensely studied question is how a protein can fold so quickly 
and effectively. Since there are too many different conformations for a protein chain 
to be tested out by the protein one by one, how can the protein fold in just seconds or 
less, are there pathways for folding? This question was first asked by Levinthal in 
1968 (Levinthal 1968), and since then different models have been put forward -e.g. 
the nucleation-condensation mechanism- where a protein folds by first forming 
important contacts between residues involved in the so called folding nucleus 
(Abkevich et al. 1994), the hydrophobic collapse (Rackovsky and Scheraga 1977), or 
the (rugged) folding funnel (Wolynes 2007). Importantly for these models is that they 
follow a two-state folding scenario, where the free energy difference between the 
unfolded state and the folded native state is referred to as the folding free energy 
change. 
There has been however an increasing attention towards the existence of 
proteins with low-energy barriers for protein folding, which is associated to a down-
hill folding scenario. During folding these proteins cross a thermodynamic barrier 
low enough to produce significant deviations from two-state folding behaviour 
(Garcia-Mira et al. 2002; Sadqi et al. 2006). Recently it has been shown that -
Lactalbumin that is a paradigm in protein folding presents a surprisingly low folding 
barrier, which appears to arise from the stabilization of partially unfolded 
conformations by electrostatic interactions (Halskau et al. 2008). 
Many encoded proteins contain more than one foldable unit (Apic et al. 
2001a). Protein structural units that independently of other such units can fold into a 
distinct, compact, and stable structure are referred to as protein domains. 
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Protein domains are the building blocks that in different combinations can 
perform highly diverse functions. The 3D structures of these domains are called 
folds. There are about 1000 folds, currently known. These folds are found in a highly 
skewed distribution, where i) superfolds are a small number of highly abundant folds 
found in many different proteins which are able to perform a vast variety of 
functions, ii) common folds are an increasing number of folds, shared by a few 
different proteins, and iii) unifolds are most folds but these are only found within one 
protein (Coulson and Moult 2002). Here protein actually means protein family, which 
will be further discussed below. 
 
Figure 2.  The 
20 amino acids in the protein alphabet have different properties and can be divided 
into clusters according to different criteria, e.g. small, polar, hydrophobic, etc. The 
amino acids are named according to the 1-letter code. Figure inspired by (Livingstone 
and Barton 1993). 
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Figure 3. Introduction to protein structure. A short peptide of four amino acids (A). 
From the N terminus: Glu (purple background), Val (blue background), Gly (green 
background), and Ala (yellow background). Each amino acid has an amino group (N 
terminus) and a carboxyl group (C terminus) (C). The amino acids are connected to 
each other by forming a peptide bond. The atoms forming the peptide bond are the 
carbonyl group (red) from aai and the amino group (blue) from aai+1. The peptide 
bond (red dotted line in (A)) has double bond character and is strong and almost 
planar. The backbone of a protein also includes the C-carbons, to which the 
different side chains are connected by the C-carbon (A). By combining the amino 
acids in different ways the  and  angles will vary (A). Depending on  and , 
higher order structures, so called secondary structure elements, -helix (B) and -
sheet (C), can form.  Figure generated in DeepView (Guex and Peitsch 1997) and 
rendered by POV-Ray (POV-Ray). 
 
The natural question to ask here is how can the superfolds be explained? Are 
all proteins that display the same fold related, or are they a random sampling of folds? 
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Has the same fold evolved multiple times? Why are just these folds so abundant? 
This is a topic of debate, where some say that these energetically stable superfolds 
can harbor high sequence divergence while maintaining the fold (Shakhnovich et al. 
2003), while others suggest that evolution has converged on these folds many times 
(Marsden et al. 2006). However, many shared physicochemical interactions and 
smaller substructural and sequence motifs as well as similarities in functions indicate 
that the domains sharing a fold also have common ancestry (Saraste et al. 1990; 
Koonin 1993; Kiel and Serrano 2006). Two important mechanisms that enable 
sequences to diversify and proteins to attain new functions are gene duplication and 
different multidomain combinations.  
1.1.3. Gene duplication – a driving force for new protein functions 
Sasumo Ohno postulated in 1970 that gene duplication is required for the 
evolution of new gene/genome functions (Ohno 1970). Gene duplications may be 
small scale events, e.g. duplicating a single gene or chromosome, but also whole 
genome events have occurred. After a complete gene has been duplicated, there is 
gene redundancy in the genome. Given the gene redundancy, the functional 
constraint on that gene is relieved. Hence, the gene duplicates can explore more of 
sequence space as there now is a back up for its function. This effect is even larger in 
the case of whole genome duplications which let entire pathways evolve with 
relieved functional constraints (Roth et al. 2007). The possible scenarios for the 
duplicated gene copies include pseudogenization, neofunctionalization, 
subfunctionalization (Ohno 1970; Hughes 1994; Force et al. 1999; Ohno 1999), 
dosage compensation (Birchler et al. 2005), and genetic robustness (Gu et al. 2003). 
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In eukaryotes the complex gene structure with introns and exons also constitutes a 
mechanism for altering function by e.g. changes in gene expression and alternative 
splicing (Lynch 2006). 
Pseudogenization 
Pseudogenization is the most common fate for one of the gene copies after 
gene duplication. By fixation of a null mutation one copy is non-functionalized. 
Eventually a pseudogenized gene will no longer be recognizable in the genome.  
Neofunctionalization 
The gene redundancy following a gene duplication allows the two gene copies 
to explore new functions. However, as one copy is devoid of the original function 
while attaining a new function, the functional redundancy is lost and the remaining 
copy must maintain the original function. The neofunctionalization mechanism is a 
way for both copies -with new, old, or slightly modified functions- to be fixed within 
the genome.  
Subfunctionalization 
Subfunctionalization also provides a mechanism for both duplicated gene 
copies to be retained in the genome. As many genes encode multidomain proteins it is 
intuitive to imagine that different domains from the two duplicate genes, or proteins, 
may interact to perform the original function. It has recently been shown that 
subfunctionalization, as a mechanism to retain both duplicates, can be followed by 
neofunctionalization, where the redundant domains, instead of the redundant gene 
can explore more of sequence space.  
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Dosage compensation 
If a gene and its regulatory region are duplicated, the expression of that gene is 
doubled. Gene duplication may also play a role in increasing the expression of genes 
where there is a selective advantage to increased expression (Wagner 2005). Dosage 
compensation is a mechanism to maintain a similar ratio of the different expressed 
genes although their copy number has been altered, as after a whole genome 
duplication. This effect is greater for regulatory genes, and can also be referred to as 
hierarchical regulatory balance. As selection occurs on one dosage-dependent 
regulator, other regulators in a balanced relationship can co-evolve. Conflicts among 
components of regulatory complexes within the genome could accelerate 
evolutionary change (Birchler et al. 2005). 
Genetic robustness 
Genetic robustness is another mechanism to retain both duplicated copies of a 
gene in a genome as a backup (Gu et al. 2003). Under this mechanism both copies are 
thought to maintain their original function and expression profile. Theoretical work 
has suggested that this mechanism is mostly applicable in species with high mutation 
rates and large effective population sizes (Elena et al. 2007). 
 
1.2. Homology 
Homology is one of the cornerstones in comparative biology and molecular 
evolution and, therefore, a brief introduction to homology and other related concepts 
will be given here in the light of gene duplications and speciation events. A 
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speciation event occurs when the genetic boundary between two sub-species becomes 
large enough to prevent reproduction. A gene duplication event occurs when there is 
an additional gene copy in the genome. This additional gene copy may result from an 
entire genome duplication or a smaller scale duplication, e.g. a chromosomal 
duplication.  
1.2.1. Orthologs and paralogs 
When a gene duplication is followed by neofunctionalization, the result is two 
paralogs, A and B. Upon a speciation event, gene A is present in the two new species, 
1 and 2. Genes 1A and 2A are orthologs and have the same function. If this gene is 
further duplicated in both lineages these new duplicates will be paralogs to each other 
within each species, but orthologs to both copies in the other species (Figure 4). This 
can be further complicated if e.g. one of the genes is lost from one of the species, or if 
its sequence has diverged beyond recognition. In order to recognize protein 
sequences as homologs using only basic sequence analysis their pairwise sequence 
identity ought to be > 35 %. Pairwise protein sequence alignments in the so called 
twilight zone (20-35%) include a large fraction of non homologous proteins, as far as 
different structures are found among the pairs (Rost 1999). 
Remote homologs 
As sequence divergence becomes large enough for making homology 
identification with sequence based methods uncertain, there is another dimension of 
proteins to utilize. It has long been recognized that protein structure is more 
conserved than sequence (Zuckerkandl and Pauling 1965; Chothia and Lesk 1986). 
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Therefore, using protein structures aids to the identification of homologous proteins 
with highly diverged sequences. Different reasons for the extensive sequence 
divergence are given in the following sections.  
 
A             ALineage 1 
specific gene 
A duplication
Lineage 2 
specific gene 
A duplication
Speciation event
1A      1B  2B         2A
 
Figure 4. Paralogs are separated by a gene duplication event and orthologs by a 
speciation event. At the time of speciation between lineage 1 and lineage 2, both 
genomes had one copy of gene A. In lineage 1, gene A was duplicated. The resulting 
genes were 1A, which maintains the original function, and 1B that has another 
function. In lineage 2, gene A was also duplicated. The resulting genes were 2A, 
which maintains the original function, and 2B that has another function. Genes 1A 
and 1B are paralogs; similarly genes 2A and 2B are also paralogs. In all other 
comparisons within this group of genes are the genes orthologs.  
 
 
1.2.2. Protein structure comparisons 
As remote homology detection can gain from comparing structures, 
homologous proteins can benefit from having their structures compared. Although it 
is generally true that structure is more conserved than sequence (Zuckerkandl and 
Pauling 1965; Chothia and Lesk 1986), there are exceptions. Not all homologous 
proteins have the same structure (Grishin 2001). The process by which homologous 
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proteins acquire significantly different structures is called neostructuralization 
(Liberles 2005), but how often it occurs remains to be investigated.  
Structural similarity 
As discussed above many folds, with the same order of secondary structure 
elements and the same connectivity, are reoccurring in different proteins, with 
different functions, and with very different sequences. Most methods have their own 
scheme for scoring the obtained similarities for two aligned structures. These scores 
are often based upon sequence identity, Root Mean Square Deviation (RMSD), 
alignment length, and number of gaps in the alignment. RMSD is a very important 
factor for the comparison. It is calculated from the coordinates of different equivalent 
atoms in the two structures and indicates how similar the structures are, regardless of 
homology. The RMSD can be calculated on just the C carbons, the peptide 
backbone, and, in some cases, the side chains are included in the calculation.  
1.2.3. Protein fold distribution 
Some authors estimate that most of protein fold space is covered by the 
currently known 1000 folds (Taylor 2007; Goldstein 2008), while others estimate that 
there are many unique folds that remain to be detected (Coulson and Moult 2002). 
Over the last few years, although the number of experimentally determined structures 
has rapidly increased, the number of folds is almost constant (PDB statistics). The 
distribution of folds among protein families is highly skewed. Some folds are very 
abundant and found in many different contexts with a variety of functions, and with 
sequences that have diverged beyond recognition of each other. Other folds are 
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unique to one particular family, and some folds are something in between (Coulson 
and Moult 2002). 
Different explanations to the fold distribution have been put forward. One 
explanation is designability. Designability is a measurement for how many sequences 
that can fold into a certain structure (Buchler and Goldstein 1999). Some folds have 
high designability which means that their sequences are robust to substitutions while 
still maintaining their folds (Melin et al. 1999; Zeldovich et al. 2006). The reason for 
the highly designable folds is very frequent and long range contacts (England and 
Shakhnovich 2003). An alternative or perhaps complementary view was asked; are 
some folds overrepresented due to the functions they can provide (Goldstein 2008)? 
Further, the role of evolutionary dynamics in the fold distribution may also be 
important. It has been shown, using lattice-models, that for a large protein population 
with high mutation rate, the evolving population is polymorphic in stability and 
subjected to frequent mutations, so the more stable and thus more mutationally 
tolerant proteins will produce more folded offspring. For a small population with low 
mutation rate, the evolving population is monomorphic in stability so all members of 
the population are equally likely to produce foldable offspring (Bloom et al. 2007). It 
seems likely that one or various combinations of designability, functionality, and 
evolutionary dynamics are needed to explain the fold distribution.   
1.2.4. Multidomain proteins 
As mentioned above, protein domains are the evolutionary units, which in 
different arrangements can perform different functions. However, it must be noted 
that many protein domains are found as stand-alone one domain proteins. 
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Evolution of multidomain proteins 
By combining domains in different genes to be expressed as proteins, domains 
are the building blocks of diversity. Multidomain proteins are the result of different 
domain combinations. In metazoans > 80% of all proteins are multidomain proteins, 
while about two-thirds of proteins in unicellular organisms contain more than one 
domain (Apic et al. 2001b; a). Multidomain proteins are formed by exon shuffling, 
recombination, fusion, and fission of genes (Long et al. 2003). One of the major 
contributions to the larger fraction of multidomain proteins in metazoans is exon 
shuffling of exon bordering domains (Ekman et al. 2007). Regardless of mechanism, 
a domain is frequently added at the N-terminus, or at the C-terminus, of a current 
protein that already has one or several domains to create a new multidomain protein 
(Ekman et al. 2007). For the aromatic amino acid hydroxylase (AAAH) family, its 
different domains are all present in some, but not all, bacteria. For many bacteria and 
all archea, the catalytic domain is not found within their genomes. Most protozoan 
(unicellular eukaryotes), and all plantae (non-animalia multicellular eukaryotes) lack 
the catalytic AAAH domain as well. However, as more protozoan genomes 
sequencing projects are finished, species with solely one full-length AAAH are 
identified, e.g. Dictyostelium diccoideum, the Leishmania species, and Monosiga 
brevicollis.  Metazoans (multicellular animals) have at least three different full-length 
AAAH genes.  
1.2.5. Protein domain organization in databases 
          Regardless of how the distribution of folds is explained, there is a need to 
classify the protein domains found with different or similar folds. If there are about 
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1000 or even 10000 different structural domains (also known as topologies or folds), 
comparing the number of folds to the number of genes in the human genome, which 
has about 20 000 -25 000 genes - not even counting the number of different domains, 
indeed reveals that some folds must be represented more than once. However, as seen 
above, many proteins are multidomain proteins and therefore a first step is to identify 
the domain boundaries in different protein structures. Once domains are determined 
the classification can begin. There is a hierarchical organization of folds and domains, 
and to further group them into families based upon their sequence similarities has 
proven very useful, as in e.g. protein structure classification databases like CATH 
(Pearl et al. 2003; Pearl et al. 2005) and SCOP (Murzin et al. 1995). Following the 
CATH hierarchy, proteins are classified into Class - based upon its secondary 
structure elements, Architecture – based upon the direction of the secondary 
elements, Topology – based upon the direction and connectivity of the secondary 
elements, and Homologous superfamily – based upon proven common ancestry. The 
homologous superfamily is further divided into sequence families (Pearl et al. 2003; 
Pearl et al. 2005). The number of homologous superfamilies found for a particular 
fold is what first led to the identification of the superfolds. In 1994, the CATH 
database contained 9 superfolds found in more that 10 different homologous 
superfamilies (Orengo et al. 1994). The three most common superfolds, the Rossman 
fold, the ferredoxin-like fold, and the immunoglobulin-like fold (Figure 5A-5C) are 
today present in over 110, 80, and almost 70 different homologous superfamilies, 
respectively. The TIM barrel (Figure 5D) is another superfold, commonly used fold 
for different enzymatic functions.  
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           A prevalent database for protein sequence families is Pfam. Pfam includes the 
entire domain sequence and not just conserved motifs. It is therefore representing 
biologically meaningful sequence annotation instead of just short sequence motifs 
alone (Sonnhammer et al. 1998). A recent feature of Pfam is Pfam clans. In a Pfam 
clan, two or more Pfam families that have arisen from a single evolutionary origin 
can be found (Finn et al. 2006). The latest version of Pfam had more than 9300 
protein families (Finn et al. 2008). This discrepancy between the 1000 known folds 
and almost 10 times as many protein families indicates that sequence divergence is a 
major factor for protein family distinction, but what drives it beyond recognition? 
1.2.6. Functional divergence on a sequence level 
          As protein sequences start to diverge there are a few requirements that must be 
fulfilled. For instance, the original function must be maintained or improved for a 
substitution to be fixed with high probability. This function may be catalytic activity, 
agonist binding, or interactions with other proteins.  Further, to maintain its structural 
integrity, the protein must also maintain its ability to fold. As described above high 
designability of a fold allows its protein sequences a higher potential to evolve 
beyond sequence recognition than for the sequences of a fold with low designability.  
           Early models describing sequence divergence simply divided amino acid sites 
into two classes, one with the potential to change and one that could not change. 
When different substitutions became fixed the sites in the class with the potentially 
varying sites would differ. As sequence space starts to be explored one substitution 
changes the probabilities for substitutions in the other positions (Fitch and Markowitz 
1970) This is called covarion behavior. The group of H. Philippe described 
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heterotachy as an important factor for sequence divergence (Lopez et al. 2002) . 
Heterotachy means that the evolutionary rates for all sites in the protein can change 
over time, where the covarion behavior represents a subclass of heterotachy (Lopez et 
al. 2002).  
A B
C D
 
Figure 5. Cartoon representation of the three most common superfolds, the Rossman 
fold (A), the ferredoxin-like fold (B), and the immunoglobulin-like fold (C), together 
with a superfold found in many catalytic domains, the TIM barrel fold (D). The 
secondary structure elements are -helix (red), -strand (yellow), loops and 
unstructured regions (grey). The N-terminus to C-terminus direction is given by the 
arrows at the C-terminus end of the -strands. PDB id’s used 1DLJ (Campbell et al. 
2000)(A), 1PHZ (Kobe et al. 1999) (B), 1K5N (Hulsmeyer et al. 2002) (C), and 
1XX1 (Murakami et al. 2005) (D). Figure generated in DeepView (Guex and Peitsch 
1997) and rendered by POV-Ray (POV-Ray). 
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Further, it should also be mentioned that sequence divergence is highly context 
dependent as interacting proteins and domains are evolving together (Lopez et al. 
2002). 
Superfold domains evolve in different environments (e.g. the surrounding 
domains) and this makes their sequences diverge further. As the same domain re-
occurs within the same genome or even within the same protein, the different copies 
of it will start to diversify. It has been found that two similar domains located next to 
each other in a protein sequence will rapidly diversify to avoid unwanted contacts or 
aggregation (Wright et al. 2005). A common way to form aggregates is by runaway 
swaps (Bennett et al. 2006). Runaway swaps are different than domain-domain 
swapping, which is a common mechanism for multidomains to dimerize (Kinch and 
Grishin 2002). Runaway swaps are frequently found in deposition diseases, as e.g. in 
prion disease (Bennett et al. 2006). Runaway swaps are the result of e.g. a two 
domain protein where the two domains, A and B, are connected by a hinge region. If 
the coordination of the hinge region changes, this opens up for dimer formation, with 
domain A from one chain and domain B from the other chain. If domain B from the 
first chain and domain A from the second chain also form the same contact it can 
prevent a deposit to form (the classic domain-domain swap). If not, runaway swaps 
may be formed, as domain B from the first chain and domain A from the second chain 
now are open binding sites where another similar chain can attach and form higher 
order structures (Bennett et al. 2006). A similar effect is likely to occur for the protein 
folds that are found in many different domains, as e.g. the superfolds. Given their 
abundance, the superfold domains may further drive their sequence divergence to 
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similar superfold domains as they have a tendency to be promiscuous and form 
unwanted contacts by e.g. inter domain-domain swapping.  
The driving force for protein designabilty is the stability of its folded state 
relative to the unfolded state. Proteins have been found to be marginally stable. How 
does marginal stability correspond to sequence divergence? 
 
1.3. Marginally stable proteins 
1.3.1. Proteins are marginally stable 
          Proteins are not rigid molecules. They are marginally stable and Fersht showed 
that their folding free energy (Gf) is between -5 and -15 kcal/mol (Fersht 1999). The 
stability (or instability) of folding is due to the contributions from the hydrophobic 
effect, hydrogen bonding, packing interactions between buried residues, and also 
electrostatic interaction energies between surface accessible residues, both in the 
unfolded and the folded states. This indicates that there is a delicate balance of 
stabilizing and destabilizing interactions which may be important for the protein’s 
biological function, but is this balance driven by nature’s selection for marginally 
stable proteins, or are proteins marginally stable as an artifact of their design?  
Why are proteins marginally stable? 
            The classic view of protein evolution is that proteins are marginally stable 
because there is a tradeoff between stability and flexibility. Therefore evolution 
selects for proteins that are stable, but not too stable. The explanation is often that 
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proteins need their flexibility to perform a certain function. Most mutations will have 
large effects on the structure and/or dynamics of the protein. Deleterious effects of 
mutations will be compensated for by conditionally beneficial mutations, as part of 
adaptive evolution (see (DePristo et al. 2005) and refs. therein). An alternative view 
of why proteins are marginally stable is given from a more evolutionarily neutral 
point of view. Here the view is that most substitutions are neutral and do not alter 
structure, function or stability. There is no selection or thermodynamic reason that 
proteins cannot be more stable; that they are not is an artifact of the evolutionary 
process, since destabilizing mutations are more common than stabilizing ones in the 
folded protein (Taverna and Goldstein 2002). This is related to designablity and 
evolutionary dynamics as discussed above.  
Proteins are dynamic 
           The marginal stability in (non-fibrous) proteins means that the energy gap to 
slightly altered conformations is small. All together the result is that many proteins 
are highly dynamic. These dynamic properties can result in equilibrium of different 
conformations for many proteins. Dynamic proteins can explore a wide range of 
different conformations. For many dynamic proteins there is coupling between at 
least two different conformations, e.g. ligand-bound and ligand-unbound 
conformations, which in many cases are provided by widely distributed binding sites.   
1.3.2. Allostery  
            Allostery is a term borrowed from Greek, where allos means other and stereos 
means solid or space. The central dogma of allosterism is that as an effector binds at 
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one site and it causes a conformational change at another site. Allostery was first 
defined as the regulation of a protein by a small molecule that differs in shape from 
the substrate, but was later redefined to include regulation of a protein through a 
change in its quarternary structure as induced by a small molecule, including the 
substrate (Monod et al. 1963). In enzyme terminology allostery is often associated 
with oligomeric enzymes showing variable ligand binding affinity that enhances or 
depresses catalytic activity. This is referred to as cooperativity (Fersht 1984). When 
the ligand binding affinity increases, the allosteric behavior is called positive 
cooperativity, and similarly, negative cooperativity is when the affinity decreases.                      
The effect of cooperativity is measured by a Hill plot. The Hill plot describes the 
binding of ligands to allosteric proteins in the region of 50 % saturation, where the 
value of the Hill coefficient (h) is given from the slop of the Hill plot. If h=1 there is 
no cooperativity; if h>1, there is positive cooperativity; and if h<1, there is negative 
cooperativity (Fersht 1984). The substrates and other effectors that cause the 
cooperativity by binding at the substrate binding site are homotropic allosteric 
modulators. Homotropic modulators typically activate the enzyme, as in e.g. positive 
cooperativity, where they can bind the active site of one subunit in an oligomer 
increasing the affinity and activity at the other active sites. Heterotropic allosteric 
modulators are effectors of the allosteric response, which bind to a site different to 
the active site where they modulate the substrate affinity and activity. Heterotropic 
modulators can be inhibitors or activators. The two classical mechanisms commonly 
used to explain allostery are the concerted mechanism (Monod et al. 1965) and the 
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sequential mechanism (Koshland et al. 1966). It is becoming evident that these two 
models are not able to explain all the different types of allosteric behavior seen today.  
The concerted mechanism 
            The concerted mechanism involves a preservation of the symmetry in the 
quaternary structure of the protein. This mechanism is appropriate for oligomeric 
proteins that are present in two different conformations: (1) the unactivated 
conformation of the protein, without the allosteric effector bound -called the T (tense) 
state- and (2) the ligand-activated conformation -called the R (relaxed) state. The T 
state must have lower ligand affinity than the R state. Last, if all binding sites in the T 
and R states, respectively, are equivalent, then this is a concerted mechanism (Monod 
et al. 1965). 
The sequential mechanism 
The sequential mechanism for allosteric behavior is based on a gradual change 
from the T state to the R state. The two underlying assumptions for the sequential 
model are that the protein exists in one conformation, prior to ligand binding. Upon 
binding the ligand a local change occurs in the subunit where the ligand is bound. 
However, the effect can be transmitted to other binding sites at the adjacent subunits 
by changes at the subunit interfaces (Koshland et al. 1966). 
The expanded view 
The thermodynamic understanding of proteins is consistent with an 
equilibrium model of different conformations and that allosterism can drive the 
increase of one conformation at the cost of another (Tsai et al. 2008). However, it is 
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necessary to note that conformations seen in allosteric proteins are present as 
populations which coexist in equilibrium. When a ligand binds to a ligand binding 
site it can redistribute the population (Gunasekaran et al. 2004). Allosterism is not 
exclusive of multidomain proteins, but also single domain proteins can show 
allosteric behavior (Gunasekaran et al. 2004; Leiros et al. 2007). It is also becoming 
evident that allostery does not need to involve a major conformational change (Tsai et 
al. 2008).  
 
1.4. Phenylalanine hydroxylase and its homologs 
Phenylalanine hydroxylase (PAH, EC 1.14.16.1) is a member of the 
tetrahydrobiopterin dependent AAAHs, together with its homologs, tyrosine 
hydroxylase (TH, EC 1.14.16.2) and trypthophan hydroxylase (TPH, EC 1.14.16.4). 
These enzymes have high physiological importance in mammals. PAH, which is 
mainly found in liver, catalyzes the first step in catabolism of L-Phe, by 
hydroxylating L-Phe into L-Tyr. Dysfunctions of PAH that cause elevated L-Phe 
concentrations result in hyperphenylalaninemia and phenylketonuria (PKU). TH, 
which is found in the central nervous system and the adrenal gland, catalyzes the first 
step in the formation of catecholamines by converting L-Tyr into L-Dopa. L-Dopa is 
decarboxylated by the aromatic L-amino acid decarboxylase (EC 4.1.1.28) and 
dopamine is the product. Dopamine can further be converted into norepinephrine and 
epinephrine, and these are all important hormones and/or neurotransmitters. Together 
with tyrosinase, PAH and TH are also important for melanin formation (Schallreuter 
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et al. 2008). The reaction catalyzed by TPH is the first and rate-limiting step in the 
biosynthesis of serotonin and the initial and uncommitted step in the synthesis of 
melatonin, by hydroxylating L-Trp into 5-hydroxytrypthophan (5-HTP). Serotonin 
has many functions as e.g. it is involved in smooth muscle contraction in intestine 
(Erspamer and Asero 1952) and in controlling mood changes such as depression and 
impaired cognitive function (Owens and Nemeroff 1994). Melatonin is important in 
regulating the circadian rhythm. Dysfunctions in melatonin production have been 
shown in sleep disorders, Alzheimer’s and Parkinson’s disease, depressive disorders, 
and various cancers (Pandi-Perumal et al. 2008). There are two tissue specific forms 
of TPH; TPH1 is found in the gut, pineal gland, spleen, and thymus, while TPH2 is 
found in the brain stem (Walther and Bader 2003). Most aspects of the AAAHs are 
conserved among them, with the main exception being their different substrate 
specificities and regulation.   
1.4.1. Domain composition  
The AAAHs include three domains. Starting from the N-terminus these 
domain are, a regulatory ACT domain (in PAH residues 30-111), a central catalytic 
domain (in PAH residues 112-408), and a C-terminus oligomerization domain (in 
PAH residues 409-452) (Figure 6). In addition, the first sequence stretch in the N-
terminus, prior to the regulatory domain is different among the AAAHs. For PAH it 
is called the intrinsic autoregulatory sequence (IARS) (Teigen and Martinez 2003). 
The IARS has a phosphorylation site and phosphorylation is part of the regulatory 
mechanism for mammalian PAH (Wretborn et al. 1980; Kaufman 1993). Also TH 
and TPH have phosphorylation sites in their N-terminus sequence stretches. In TH, 
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phosphorylation decreases its inhibition by catecholamines (Ramsey and Fitzpatrick 
1998), and for both TH and TPH phosphorylation regulates their interaction with 14-
3-3 proteins (Kleppe et al. 2001; Winge et al. 2008) .      
Regulatory domain
Oligomerization domain
Catalytic domain
 
Figure 6. Multiple sequence alignment of human AAAHs. The following sequences 
were used and are numbered accordingly: TH (NP00531), PAH (NP000268), TPH2 
(NP775489), and TPH1 (NP004170). Bars (black) denote domain boundaries and the 
regulatory domain (Melin et al.), the catalytic domain (yellow), and the 
oligomerization domain (orange) are shown. The sequences are colored by 
conservation. 
 
The regulatory domain 
The regulatory domain in PAH is classified as an ACT domain (Kobe et al. 
1999). The initial classification of the ACT domain included the regulatory domain of 
PAH and TPH, but not the regulatory domain of TH (Aravind and Koonin 1999). The 
sequence divergence of this domain in the different AAAHs is very high (Figure 6) 
and this is probably related to the superfold topology of this domain. The ACT 
domains have highly abundant 2-layer / plaits topology (Figure 5, 7A) (also called 
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the ferredoxin-like fold), with an anti-parallell β-sheet with two α-helices on top. 
There are more than 70 different homologous superfamilies with this fold in the 
CATH database. ACT domains are, according to their definition, regulatory domains 
that form dimers and bind amino acids at the dimer interface. They are often found to 
modulate the activity of other proteins or domains e.g. in allosteric enzymes. Now, 
this definition does not entirely apply to the ACT domain in mammalian AAAH. No 
ligands are known to bind to the regulatory domains of these enzymes. For PAH, it 
has been speculated that L-Phe could bind to an additional effector site, possibly 
located in the regulatory domain (Tourian 1971; Shiman 1980; Parniak and Kaufman 
1981; Kaufman 1993; Kappock and Caradonna 1996) but it has been shown that the 
stoichiometry of L-Phe to PAH subunit is 1:1, which does not support an effector 
binding site in addition to the active site (Thorolfsson et al. 2002). However, L-Phe 
allosterically modulates the activity of PAH by positive cooperativity (Wretborn et al. 
1980; Kaufman 1993; Kappock and Caradonna 1996; Knappskog et al. 1996), but the 
mechanism is still unclear. The regulatory ACT domain is connected to the catalytic 
domain by a long flexible linker sequence, but the relative orientation of these two 
domains is not certain since no full-length AAAH structure is available. The 
regulatory ACT domain is also in contact with the catalytic domain of the adjacent 
chain in the dimer and with the oligomerization domain of its own chain (Figure 6).   
The catalytic domain  
The catalytic domain has a unique fold, only found in the AAAH’s (Figure 
7B). As the name implies this is where the active site is located. The catalytic 
domains in two adjacent chains do not interact with each other. Only mammalian 
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PAH has an allosteric activation mechanism to our current knowledge, but for TH  
negative cooperativity for the binding of the cofactor (6R)-tetrahydrobiopterin (BH4) 
has also been shown (Flatmark et al. 1999). The sequences of the different catalytic 
AAAH domains are highly conserved (Figure 6). 
The oligomerization domain 
The oligomerization domain consists of two structural motifs. From the N-
terminus there is a small -hairpin, called the -ribbon (Figure 7C), with highly 
conserved sequence (Figure 6). The -ribbon is followed by a long -helix with 
rather divergent sequence (Figure 6, 7C). The -ribbon is involved in dimer 
formation and the long -helix is involved in tetramerization by forming a leucine 
zipper (Fusetti et al. 1998).    
Domain assembly 
TH and TPH form homotetramers. Mammalian PAH has been found to exist in 
vitro as a dimer-tetramer equilibrium, where the dimer represents a low-affinity and 
low-activity state while the tetramer represents a high-affinity and high-activity state. 
As the L-Phe concentration increases the equilibrium is shifted towards the tetrameric 
form (Doskeland et al. 1982; Martinez et al. 1995). A composite model of the full 
length dimer (Fusetti et al. 1998; Kobe et al. 1999) is shown in Figure 7D and of the 
tetramer, which is a dimer of dimers  (Goodwill et al. 1997; Fusetti et al. 1998), is 
seen in 7E. 
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1.4.2. The catalyzed reaction  
The enzymatic reaction is highly similar in all AAAHs, with the substrate 
being the only difference (Fitzpatrick 2003; Teigen et al. 2007). The reactions 
performed by the AAAHs are dependent upon the different substrates, the cofactor 
BH4, non-heme iron, and molecular oxygen. In PAH, L-Phe is hydroxylated in the 
para position and converted to the product L-Tyr (Figure 8). In TH, L-Tyr is 
hydroxylated into the product L-Dopa (Figure 8). In TPH, L-Trp is hydroxylated into 
the product 5-OH-TRP (Figure 8).  Regarding the order of reactant binding, it has 
been shown that the pterin cofactor binds first both in the case of TH (Fitzpatrick 
1991) and bacterial PAH (Volner et al. 2003). The mechanism of reaction and order 
of substrate binding is however not clear for mammalian PAH and TPH. A 
requirement for the cofactor to bind before the amino acid substrate might explain 
why the AAAH are inhibited by high substrate concentrations (Fitzpatrick 2003).  
1.4.3. The PKU phenotype 
Elevated concentration of L-Phe causes neurological damage, if left untreated 
(Scriver and Kaufman 2001). The reasons behind hyperphenylalaninemia can be a 
dysfunction in PAH, as in phenylketonuria (PKU), or in the supply of the cofactor 
BH4 (Thony et al. 2000). PKU was discovered in 1934, by the Norweigan Asbjörn 
Föllingsen (Folling 1934). It is as an autosomal recessive metabolic disorder. The 
typical PKU phenotype is often consistent with growth failure, light pigmentation, 
microcephaly, seizures, global development delay and severe intellectual impairment 
(Williams et al. 2008).  Many different mutations can cause PKU and in general the 
mutations in human PAH result in decreased stability and misfolding of the enzyme 
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(Pey et al. 2007). The known mutations associated with PKU can be found on the 
PAH knowledge based website (http://www.pahdb.mcgill.ca/). 
 
  
Figure 7. The domain organization in PAH; the regulatory domain (A), the catalytic 
domain (B), and the oligomerization domain (C), colored according to secondary 
structure (-helix; orange, and -strand: blue). The arrangement of these domains in 
one chain, as part of the modeled full-length dimer (D) and tetramer (E). The dimer is 
colored as follows; chain A: regulatory domain (orange), catalytic domain (yellow), 
and oligomerization domain (brown), and chain B (blue). The tetramer is colored as 
follows; chain A: regulatory domain (orange), catalytic domain (yellow), and 
oligomerization domain (brown), and chain B (grey), chain C (light blue), and chain 
D (dark blue). Figure generated in DeepView (Guex and Peitsch 1997) and rendered 
by POV-Ray (POV-Ray) 
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Deficient BH4 production affects the activity of all AAAHs and can result in 
Parkinson’s disease, autism, depression, and Alzheimer’s disease (Thony et al. 2000). 
While BH4 deficiency may be treatable by supplying BH4 or derivatives thereof  
((Thony et al. 2000) and refs. therein), the classical treatment for PKU patients is to 
exclude or minimize L-Phe and protein in their diets, and supplement the other 
essential amino acids. However, it has recently been shown that some forms of PKU 
can respond to pharmalogical doses of BH4 by a multifactorial therapeutic effect, 
including a chaperone-like effect of the cofactor (Erlandsen et al. 2004; Scriver 
2007). 
1.4.4. PAH regulation 
Positive cooperativity 
As mentioned above, mammalian PAH, in vitro, is found as dimers and 
tetramers in equilibrium, an equilibrium which is driven towards the tetrameric form 
in the presence of L-Phe (Knappskog et al. 1996). Mammalian PAH is activated by i) 
its substrate, L-Phe, and ii) phosphorylation at Ser16, with these two activation 
mechanisms operating synergistically (Kaufman 1993; Kappock and Caradonna 
1996). L-Phe binds with positive cooperativity to mammalian PAH. The hill-
coefficient (h) for the cooperative binding of L-Phe to human and rat PAH is about 
2.0 (Kaufman 1993; Knappskog et al. 1996; Thorolfsson et al. 2002).  
However, the molecular basis for the positive cooperativity and substrate 
activation of this enzyme remains unresolved, partly because of the so far 
unsuccessful task to crystallize the tetrameric full-length enzyme in the presence and 
the absence of L-Phe (Flatmark and Stevens 1999). Nevertheless, site directed 
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mutagenesis and molecular dynamics simulations have been used to partly investigate 
the molecular basis for the activation of human PAH by L-Phe, and the homotropic 
positive cooperativity mechanism for the substrate (Thorolfsson et al. 2003). 
 
Figure 8. The reactions catalyzed by the AAAHs. PAH converts L-Phe to L-Tyr, 
TH converts L-Tyr to L-Dopa, and TPH converts L-Trp into 5-OH-Trp using 
molecular oxygen as cosubstrate. The cofactor, BH4, is utilized by all mammalian 
AAAH. In addition, Fe2+ at the active site of the enzymes is necessary for the 
reaction. 
 
Activation by phosphorylation 
As mentioned above, the IARS contains a regulatory phosphorylation site for 
mammalian PAH. The cAMP dependent kinase A (PKA) phosphorylates PAH at 
Ser16. Upon phosphorylation PAH is activated and the activation mechanisms by 
+ O 2  
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TH 
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L - Tyr                                                             L- Dopa 
L - Trp                                    5 - OH - Trp 
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phosphorylation and L-Phe activation are interdependent and synergistic (Phillips and 
Kaufman 1984; Doskeland et al. 1996). As supported by recent site-directed 
mutagenesis and computational structural biology studies, the IARS covers the active 
site in the unphosphorylated state and phosphorylation at Ser16 induces local 
structural changes that result in a higher accessibility of the L-Phe binding site 
(Miranda et al. 2002; Miranda et al. 2004). PAH has at least one more regulatory 
mechanism, provided by its cofactor. 
Inhibition by BH4 
BH4 exerts a regulatory inhibiting mechanism and is believed to interact with 
residues in the IARS, which causes the entire regulatory domain to move closer to the 
catalytic domain, hence hindering PKA access to the phosphorylation site, 
barricading L-Phe binding at the active site and stabilizing the enzyme (Mitnaul and 
Shiman 1995; Miranda et al. 2002; Teigen and Martinez 2003). 
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2. Methods and Theoretical considerations 
2.1. Protein sequence alignments 
All comparisons of protein sequences require the amino acid positions to be 
aligned in columns, in a so called sequence alignment. The main goal of a sequence 
alignment is to group homologous positions in horizontal sequences into vertical 
columns. The information content is higher in protein sequences than in DNA 
sequences, given the number of character states and physicochemical properties.  For 
this thesis all sequence analysis have been performed on protein sequences, although 
many of the methods presented below are applicable to nucleotide data as well. When 
the sequence divergence is too high to generate a good sequence alignment, structural 
alignments can improve the results.  
2.1.1. Sequence alignments  
Sequence alignments can be pairwise of just two sequences or multiple if they 
contain more sequences. Sequence alignments that span the entirety or most of the 
length of sequences to be aligned are called global alignments. When searching for 
re-occuring motifs, e.g. in a BLAST search (Altschul et al. 1990), local alignments 
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that match a smaller more conserved sequence section are used. Dynamic 
programming was for long the foundation for all sequence alignments. The two most 
widely used dynamic programming algorithms are Needleman-Wunsch (Needleman 
and Wunsch 1970) for global alignments and Smith-Waterman (Smith and Waterman 
1981) for local alignments. These algorithms search for the best path between two 
sequences by using an amino acid substitution matrix for matching positions in the 
different sequences and a scoring function for indel events (also known as gaps). 
Today more sophisticated multiple sequence alignment programs that use e.g. the 
phylogeny of the sequences (i.e. Muscle (Edgar 2004)) or structural information (i.e. 
Expresso (Armougom et al. 2006)) are also available. These are also dependent upon 
amino acid substitution matrices, which are further discussed below. 
2.1.2. Structural alignments 
Comparing different proteins with similar structure can provide important 
information. This requires that the protein structures are aligned or superimposed. 
The easiest and fastest way is to align the sequences and then superimpose the 
structures based upon the sequence alignment. This method is however not 
recommended for less similar sequences. Instead, methods that compare the local 
environment e.g. distances and angles of nearby residues in the 3D protein space have 
been developed.  
Aligned fragments pairs 
A common way of performing structural alignments is to initially identify the 
smaller fragments that show high similarities in their local environments surrounding 
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the C-carbons in the two structures to be aligned. The structural alignment is formed 
by connecting the fragments together. This has been the underlying procedure for 
different methods, e.g. Dali (Holm and Sander 1993), CE (Combinatorial Extension) 
(Shindyalov and Bourne 1998) and FATCAT (Flexible structure AlignmenT by 
Chaining Aligned fragment pairs allowing Twists ) (Ye and Godzik 2003). However, 
FATCAT is different than the other two methods in the way it lets the user decide if 
the structures are to be considered rigid bodies or not. By allowing twists, FATCAT 
permits more flexibility between the two structures in the alignment, which can be 
very important in e.g. homology searches. A comparison of FATCAT to two different 
rigid structure alignment programs, DALI and CE, showed that FATCAT performed 
better alignments. DALI stopped at hinge positions, where FATCAT inserted a twist, 
while CE continued and thereby aligned non-homologous residues (Ye and Godzik 
2003). 
SSAP 
The Sequential Structure Alignment Program (SSAP) is used to align protein 
structures in the CATH database. The structural alignment is generated by double 
dynamic programming. It compares the surrounding environment (distances to the 
neighboring residues) of each C-carbon in both structures and uses this information 
to create the sequence alignment based on structural criteria (Taylor et al. 1994; 
Orengo and Taylor 1996). Besides differences in the implementation of e.g. SSAP 
and FATCAT, an additional important difference is the starting point for SSAP, the 
C-carbon, instead of the commonly used C-carbon (Figure 3). A dummy C-
carbon is used for Gly.  
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MUSTANG 
Similarly, to generating multiple sequence alignments, also multiple structure 
alignments can be constructed. One algorithm that constructs these is MUSTANG 
(MUltiple STructural AligNment AlGorithm). By aligning residues based upon 
similarities in patterns of both residue-residue contacts and local topology, 
MUSTANG compares the structures to be aligned in a pairwise manner. The pairwise 
alignments are scored after similarity. Finally, the multiple structural alignment is 
constructed from the pairwise alignments, based upon their score (Konagurthu et al. 
2006).  
 
2.2. Tree-building 
In order to reconstruct the different relationships between genes or proteins, a 
phylogenetic reconstruction is performed. The most commonly used methods can be 
divided into 2 categories: distance methods and discrete methods. Among the 
distance methods, Neighbor-Joining (NJ) and Unweighted pair group method with 
arithmetic mean (UPGMA) are prevalent. The discrete methods are parsimony and 
maximum likelihood (ML) or Bayesian based methods, which both use a model of 
evolution to find the optimal solution.  
2.2.1. Distance methods  
The distance methods reconstruct trees from the pairwise distances (e.g. the 
sequence identities) in a matrix between the different genes or proteins. These are not 
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recommended methods for larger phylogentic analysis, since sequence evolution is 
oversimplified when reduced to a number. NJ is more a clustering method than a tree 
building procedure and UPGMA applies a constant rate of evolution, according to a 
molecular clock, which is rarely true. However, these methods are fast and easy to 
use, e.g. as implemented in the Phylip package (Felsenstein 1996). 
2.2.2. Discrete methods 
The discrete methods use character data, gene or protein sequences, to resolve 
the relationships between the homologous sequences in an alignment. As noted 
above, an alignment of amino acid sequences contains more information than a non 
codon-based nucleotide alignment. The same is true for tree building purposes.  
Parsimony 
Parsimony tries to find the right tree from the sequence data that has the fewest 
number of substitutions. However, parsimony thereby ignores branch length 
differences -such as multiple events along a long branch being more likely than on a 
short branch- for the data and it has problems finding only one solution (Page and 
Holmes 1998). 
Maximum likelihood and Bayesian methods 
These are computationally expensive methods, but they often outperform all 
other tree building methods. Much of what applies to maximum likelihood also 
applies to the Bayesian method. The major difference between the two is the use of 
prior probability and the characterization of a distribution. For ML, the following 
equation is used;  
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 LD = f(Xτ, ν, θ)                                                      (Eq. 1) 
This equation is to be interpreted as follows: if given some data (X) and tree topology 
(τ), branch length (ν), and model of evolution (θ), then the likelihood (LD) is the 
probability of obtaining X given τ, ν, and θ.  This is also called the likelihood 
function (Page and Holmes 1998). The likelihood function is also found in Bayes’s 
rule, which is used for the Bayesian phylogenetic inference: 
 f(τ, ν, θ X) =  [f(τ, ν, θ)  f(Xτ, ν, θ)] /  f(X)                        (Eq. 2)                                 
where f(τ, ν, θ X) is the posterior probability, f(τ, ν, θ) is the prior probability,  
f(Xτ, ν, θ) is the likelihood function, which describes the probability of the data 
under different parameter values, and  f(X) is the total probability of the data summed 
and integrated over the parameter space (Ronquist and Huelsenbeck 2003). In 
MrBayes, this is coupled to a Markov Chain Monte Carlo (MCMC) technique. By 
applying a Metropolis-Hastings sampler, MrBayes updates single parameters or 
blocks of related parameters in each generation. If for the current generation the 
Markov chain has the parameters τ, ν, θ, then a new value for θ (θ*), picked from a 
proposal distribution q(θ*θ), will be accepted with the following probability (r): 
r = min (1, f(θ*)/f (θ) f(Xτ, ν, θ*)/f(Xτ, ν, θ) q(θθ*)/q(θ*θ) )       (Eq. 3) 
The MCMC chains will run until the chain converges, or for as many generations that 
have been specified by the user. Further, the user can specify how often to keep a 
sample (a tree topology with its corresponding probability). These are used to create a 
consensus tree for the data when finished. As the initial chains are a bit unstable, it is 
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wise to disregard the first samples, called the burnin phase. The consensus tree will 
have posterior probabilities of each node (Ronquist and Huelsenbeck 2003). 
However, both ML and Bayesian phylogenetic inference require a specified model of 
evolution. 
 
2.3. Models of evolution 
An evolutionary model usually contains a substitution matrix and the 
substitution rates for the data. An amino acid substitution matrix gives the probability 
of going from one amino acid to another and how these probabilities are estimated 
designates the model. For an amino acid substitution matrix the dimensions are 20x20 
and each transition is given a probability (P). The rate matrix (Q) consists of two 
factors, the observed substitutions (Sij) multiplied by the frequency of the resulting 
amino acid (pij), hence  
(Qij=Sij x pij)                                                               (Eq. 4) 
 and  
P()=e(Q)                                                                                (Eq. 5) 
where  represents the branch length. The amino acid frequencies, pi, are often 
estimated form a large dataset and not recalculated. Margret Dayhoff was a pioneer in 
the field of estimating empirical substitution matrices from homologous global 
alignments in a phylogenetic (parsimony based) context in the 1960’s and 1970’s. 
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This procedure was repeated in 1978 and the resulting substitution matrices are 
generally referred to as Dayhoff or PAM (Point accepted mutations per 100 residues) 
matrices, e.g. PAM250 equals a 20 % sequence identity while PAM80 equals 50 % 
sequence identity (Dayhoff et al. 1978). A more recent but similarly constructed 
substitution matrix is the JTT matrix, named by its authors Jones, Taylor, and 
Thornton (Jones et al. 1992). Another commonly used substitution matrix also 
derived from real data is BLOSUM (BLOck SUbstitution Matrices) (Henikoff and 
Henikoff 1992). These are estimated from local alignments of similar proteins at 
different thresholds, but not in a phylogenetic context. These matrices are referred to 
as e.g. BLOSUM62 when derived for a threshold of 62 % sequence identity. It is 
worth noting that these empirically derived matrices have been found to outperform 
matrices based upon physicochemical properties. Whelan and Goldman proposed a 
model based upon maximum likelihood in combination with a counting approach to 
make more accurate substitution matrices without the computational cost associated 
with a pure ML approach (Whelan and Goldman 2001). This matrix is referred to as 
WAG.  
Here we have presented a few of the commonly used substitution matrices, but 
there is an enormous variety of substitution matrices to choose from. The appropriate 
model for the data can be tested by performing a model test (Posada and Crandall 
1998). For proteins ProtTest is the state of the art (Abascal et al. 2005). ProtTest 
suggests a model based upon an Akaike statistical test (AIC) utilizing the relationship 
between the likelihood (L) and the number of parameters (K) for some of the most 
common substitution matrices: 
 55 
AIC = -2lnL+2K                                               (Eq. 6) 
This is also done with the different combinations of: frequency, the model will fit the 
data better by re-estimating amino acid frequency from the actual data; invariant, the 
model will fit the data better by specifying a proportion of invariant sites; and 
gamma, the model fit the data better by being divided into different rate categories. In 
order to reduce computational complexity four discrete rate categories are often used, 
instead of a continuous gamma distribution (Yang 1994). The shape parameter of the 
gamma distribution is called  and provides information on the evolutionary rate 
distribution in the data.  
 
2.4. Modeling protein structure 
The information in a linear protein sequence provides much less information 
that in its 3D form. There is a major effort undergoing right now to determine a large 
number of protein structures, carried out by Structural Genomics Consortiums all 
over the world. Today there are about 50000 experimentally determined protein 
structures compared to 5800 in 1998 according to the Protein Data Bank 
(www.pdb.org) (Berman et al. 2000). In 1998 there were almost 500 different folds 
classified. Today there are about 1000 different folds. Since 2005 very few new folds 
have been discovered, while the number of protein structures has increased with 
almost 20000 structures. This tells us that there is much to gain from comparative 
modeling or homology modeling, since its rationale is to identify a homolog with 
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known structure upon which the sequences without experimentally determined 
structures can be modeled. Given that the extent of neostructuralization still needs to 
be determined some caution should be used when applying homology modeling 
procedures.  
2.4.1. Homology modeling 
Swiss-Model is a homology modeling server (Schwede et al. 2003). It allows 
the user to perform a fully automated step where only the sequence, the so called 
target, needs to be provided. A structural homolog, the so called template, if 
available, will be identified by the server. The modeling procedure is rather simple as 
the coordinates from the templates C atoms are transferred to the targets C atoms. 
Thereafter the side chains are added from a rotamer library, which has the most 
common conformations for the amino acids. If there are any insertions in the target, 
these are modeled as loops, by searching a database of experimentally determined 
loop structures. Finally, when all side chains are in place the model is energy 
minimized. However, the automated mode has limited use since it can not build 
biological units in the case of oligomers. In order to build biological units, the project 
mode must be used and the user must build the modeling project in Swiss-Modeller’s 
own protein structure viewer and builder, DeepView (Guex and Peitsch 1997). This 
mode leaves lots of interesting features for the user to work with. First a structural 
homolog must be identified, from here on referred to as the template, and its sequence 
must be aligned with the protein to be modeled, the so called target.  
The alignment is very important in homology modeling. If the alignment is 
wrong, e.g. if non-homologues residues are aligned, it will result in an inaccurate 
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model. Therefore, it is sometimes important to use more sequences and to build a 
multiple sequence alignment instead of a pairwise sequence alignment since the 
former provides more information. The template is loaded into DeepView (Guex and 
Peitsch 1997). The target is loaded onto the template and the user can modify the 
alignment in DeepView accordingly to the pre-generated alignment before submitting 
it to the Swiss-Modeler server. Once the model is done it can be analyzed in 
DeepView. Perhaps it needs to be further optimized, in the way of changing the 
alignment or template, until a reasonable model is achieved. In DeepView many 
different operations such as fusing different templates and building biological units 
can be done. These are important steps in protein structure modeling since it adds to 
the functionality of the resulting models.  
PAH structures        
No full-length structure, with all three domains, is available for PAH or any 
AAAH in the PDB. Nevertheless, the available truncated structures have allowed the 
preparation of composite full-length models, as e.g. in (Flatmark and Stevens 1999; 
Thorolfsson et al. 2002; Kim et al. 2006). Our models from Paper II are shown in 
Figure 7D and 7E. There are various structures of catalytic domains (Figure 7B) with 
different combinations of pterin cofactors, presence and oxidation state of the Fe, and 
substrate analogs, mostly from human PAH. There are two structures of the 
regulatory domain (Figure 7A) in conjunction with the catalytic domain from rat 
PAH (Kobe et al. 1999). Only one structure of human PAH with the catalytic domain 
and the entire oligomerization domain is available (Fusetti et al. 1998) (Figure 7C). 
This structure shows two dimers, which each are internally symmetrical, but the 
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tetramer is asymmetrical. The biggest difference of the two different dimers is the 
positioning of the tetramerization -helix in the oligomerization domain (Fusetti et al. 
1998). In one of these dimers the oligomerization helices are kinked at position T427 
and G442. The first kink leads to a rotation of the catalytic domain of 22˚ relative to 
the oligomerization domain and the second kink in the helices themselves leads to a 
20˚ rotation which may be important for the interactions between the helices in the 
tetramer. Both kinks contribute to make the helices reach further away from the 
catalytic domain as to interact with the corresponding helices in a tetrameric 
conformation similar to what is seen for the structure of the catalytic and 
oligomerization domains in TH (Goodwill et al. 1997). The straight tetramerization 
-helices in one dimer are on the other hand too close to the catalytic domain to be 
involved in forming a tetrahelical bundle as seen for TH. By combining these 
structures in various ways we constructed our working models of full-length 
tetrameric PAH at different conformational –and probably functional-  states (see 
paper II, below).  
Protein docking 
When combining various domains together to form full-length protein chains, 
it is sometimes necessary to find alternative ways of docking those domains together. 
In addition, when composing dimers or tetramers of full-length subunits, some 
domains may clash in the higher order structure. For PAH all available structures are 
truncated at one end or another and therefore we used ZDOCK to explore alternative 
quaternary structures for our models. ZDOCK utilizes an unbound docking approach. 
Unbound docking is for protein structures, models, and domains, which were not 
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crystallized together. This leaves many surface side chains to optimize in the search 
for probable interactions, if they are allowed to be flexible. ZDOCK instead uses a 
soft docking approach which allows six rotational/translational degrees of freedom in 
addition to a less strict target function between the two domains or proteins to be 
docked. The target function for ZDOCK considers shape complementarity (the 
rotational and translational conformations), desolvation free energy for atoms at the 
interface, and electrostatics, and is based of a Fast Fourier Transform algorithm 
(Chen and Weng 2002; Chen et al. 2003).    
  
2.5. Diverge analysis – prediction of residues involved in functional 
change 
When comparing sequences, conserved sites are often taken as functionally 
important, while varying sites are not. When the sequence family is large enough, the 
sequences can often be divided into subgroups or clusters based upon their 
evolutionary and functional relationship. By forming clusters we can ask what is 
different among the sequences in the different clusters as a lead to explain the 
experimentally seen functional changes. The Diverge software estimates the 
probability of different sites in an alignment under a certain tree topology being 
involved in functional divergence (Gu et al. 2003; Gu 2006). Functional divergence 
in protein sequences can be divided into two main categories, types I and II 
functional divergence. Type I functional divergence, corresponds to site specific rate 
changes and type II functional divergence to site specific physicochemical property 
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changes when comparing different sequence clusters (Gu 2006). Both the change 
from being a conserved site in one cluster to being a variable site in another cluster 
(Type I) and the change from a conserved small apolar amino acid to a big charged 
amino acid (Type II) indicate that the functionality of these sites has changed 
between the two different clusters. We used Diverge 2.0 (Gu 2006) to detect type II 
functional divergence in PAH between the nematode cluster and the mammalian 
cluster. The different amino acid classes used in Diverge are preset and contain the 
following groups: charge positive (K, R, and H), charge negative (D and E), 
hydrophilic (S, T, N, Q, C, G, and P), and hydrophobic ((A, I, L, M, F, W, V, and Y) 
(Gu 2006). A cluster specific change from one amino acid group to another is called a 
radical change. The sites that differ between the clusters are given a score (S) that can 
be converted to the posterior probability (PII) of that site being involved in a 
functional change by PII = S/1+S (Gu 2006). In our case a limitation for the 
application of this method was the number of nematode PAH sequences as we only 
had four of these. However, by combining our sites into 3 different classes the type I 
divergence was represented as well. Class 1 were the sites with cluster-conserved 
radical changes, class 2 were sites with radical changes but not strictly conserved 
within each cluster, and class 3 were sites with conserved physicochemical properties 
but with different cluster-specific residues. Class 2 therefore covers many of the type 
I sites.    
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2.6. Electrostatic interaction energies 
The residue specific electrostatic interaction energies for accessible ionizable 
residues has been calculated in this work using an implementation of Tanford-
Kirkwood model (Tanford and Kirkwood 1957) together with the Bashford-Karplus 
(reduced-set-of-sites) approximation (Bashford and Karplus 1991) as described 
(Ibarra-Molero et al. 1999), using a program kindly provided by Jose Manuel 
Sanchez-Ruiz (University of Granada). This approach calculates the interaction 
energies between unit charges placed on the protonation sites of the ionizable groups 
using the Tanford-Kirkwood model, obtaining an average charge on each ionizable 
group, the effective pK values and the pairwise interaction energies using the 
Tanford-Roxby mean field procedure. The following parameters were used; atomic 
van der Waals radius according to Chothia (Chothia 1976), solvent molecule radius 
1.4 Å, temperature 298 K, pH 7, ionic strength 0.2, and dielectric constants for the 
protein and solvent 4 and 78.5, respectively. Gurd’s accessibility correction (Matthew 
and Gurd 1986) was applied. The energy of charge–charge interaction of group i with 
the rest of the ionizable groups in the protein <Wi> can be used to estimate the total 
charge–charge interaction energy in the proteins (<Wq − q>):                    
                                                         n 
                          <Wq-q> = ½ <Wi>                                                       (Eq. 7) 
                                                                                    i=1
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3. Aims 
3.1. The evolution of the AAAHs 
            Earlier attempts at resolving the phylogeny of the AAAH family have 
suffered from the lack of an appropriate outgroup, as they have focused on metazoans 
with three or more full-length AAAH genes and sometimes included the bacterial one 
domain PAH gene (Grenett et al. 1987; Patton et al. 1998; Wiens et al. 1998). The 
suggested ancestral substrate specificities were inconsistent. Hence, the determination 
of the genome sequencing of the social amoeba Dictyostelium discoideum, which 
only contains one AAAH gene, prompted us to resolve the phylogeny and the 
ancestral specificity of this enzyme family (Paper I). 
  
3.2. The function of the regulatory ACT domain in PAH  
           The essence of this thesis was to generate further insights regarding the 
regulation, in particular the cooperative response, of PAH provided by its regulatory 
domain by using a comparative approach. The regulatory domain has been classified 
as an ACT domain homolog, which certainly is an adequate classification from the 
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structural point of view. However, from a functional view, the ACT domain of PAH 
does not appear to fit the strict description of this domain. There is a debate in the 
field regarding the ability of PAH to bind L-Phe to an effector binding site at the 
regulatory ACT domain. Various authors claim that there is a L-Phe binding site in 
the regulatory ACT domain (Tourian 1971; Shiman 1980; Parniak and Kaufman 
1981; Kaufman 1993; Kappock and Caradonna 1996; Gjetting et al. 2001) and the 
assumption that PAH could bind L-Phe to the regulatory domain seemed correct 
based upon the ligand-binding properties of the ACT domain in other proteins. 
However, previous experimental results from our group (Thorolfsson et al. 2002) did 
not fit into this context and we set out to investigate this domain further. First, we 
performed a comparative study of the ACT domain from PAH and from two other 
allosterically regulated ACT domains, D-3-phosphoglycerate dehydrogenase 
(3PGDH) and the bifunctional chorismate-prephenate dehydrogenase (P-protein), 
which highlighted significant motifs in the sequences and corroborated important 
evolutionary relationships among these proteins (Paper III). Further, the ACT domain 
has a superfold topology, the so called ferredoxin-like fold, and domains with this 
fold are present in many different protein families and also as standalone domains. 
We explored more distantly related potential ACT domain homologs to gain further 
insights to the possible (present and ancient) functions of this domain in PAH (Paper 
IV). In addition, it was discovered that PAH in Caenorhabditis elegans was devoid of 
positive cooperativity and it was always found as a tetramer (Calvo et al. 2008). This 
provided an excellent system to study the differences between an allosterically 
regulated PAH in mammals and a non cooperative PAH with high activity in 
 64 
nematodes. Being in the post-genomic era we could gather enough sequences of PAH 
from both mammals and nematodes to predict residues involved in generating the 
mammal and nematode specific phenotypes of PAH. As a variety of different 
structures of the different domains in PAH are available, we aimed at generating full-
length models to study the 3D location of the residues predicted to have changed their 
function between nematodes and mammals. From the structural models, the residue 
specific electrostatics interaction energies were calculated to add another comparable 
dimension to our analysis of these two groups in order to get further insights to the 
promotion of the allosteric response in mammalian PAH that involves all three 
domains (Paper II).  
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4.1.1. Residue denomination 
For this and following sections, various positions in the PAH sequence will be 
discussed. All numbering refers to the human PAH sequence, and 1-letter codes for 
amino acid residues are used. When amino acid differences are present at a position 
compared between species or by a mutation, the amino acid in human or mammalian 
PAH is given first and the other species amino acid is given after the position, e.g. 
A322S refers to position 322 in human PAH, where human has an A and the other 
species has a S.  
 
4.2. The phylogeny of the aromatic amino acid hydroxylases (Paper 
I)  
 Previous attempts to reconstruct the AAAH phylogeny suffered from not 
having an appropriate outgroup. TH has often been assigned as the ancestral function, 
but this selection lacks experimental evidence. Further, there have been different 
explanations put forward to the series of events leading to the set of AAAH genes in 
the mammalian genomes seen today. By identifying and characterizing the first 
AAAH gene form a eukaryotic genome with only one AAAH gene, D. discoideum, 
we have found an outgroup to root the AAAH tree. We believe this is close to the 
ancestor of the metazoan AAAH because i) it is only present in one gene copy and ii) 
D. discoideum is a close outgroup to metazoans. This gene was experimentally 
characterized and the phylogeny of the AAAHs completed. Our MrBayes tree places 
D. discoideum PAH (DictyoPAH) as the natural outgroup to all metazoan AAAHs, 
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with the PAH branch being the closest, allowing us to resolve the AAAH phylogeny. 
The most parsimonious explanation is to assume that the last common ancestor of 
DictyoPAH and the AAAH genes in metazoans had PAH activity and that the TH 
and TPH functions are derived from it. By analyzing only complete eukaryotic 
genomes and the chromosomal location of the AAAH genes we could envision how 
the AAAH genes have evolved. In short, the ancestral AAAH gene was duplicated 
twice during the Cambrian explosion, separating protozoans and metazoans. By a 
neofunctionalization mechanism, these duplications gave rise to TH and TPH. Hence, 
e.g. nematodes have one PAH, one TH, and one TPH gene, located on the same 
chromosome. A whole genome duplication took place in the chordate-vertebrate 
lineage (McLysaght et al. 2002). In mammals, this eventually led to pseudogenization 
and loss of the initial TH copy and the duplicated PAH copy. The only gene that was 
successful in maintaining both its gene copies in the genome was TPH by the two 
copies having different tissue specificity. Birds and probably marsupials have kept 
the initial TH copy as well.  
 It should be noted that PAH from D. discoideum is devoid of positive 
cooperativity and the cofactor specificity is different from other eukaryotic AAAHs. 
D. discoideum synthesizes another variant of biopterin, i.e. DH4, not found in other 
eukaryotes (Klein et al. 1990) and DictyoPAH shows higher activity with DH4 than 
with BH4. We identified interesting differences between the PAH from human and D. 
discoideum: i) the S251A and A322S substitutions, which seem responsible for the 
change in cofactor preference, and ii) an additional disulfide bridge in DictyoPAH 
located close to 322S, namely 324C. In DictyoPAH, 324C (corresponding to I234 in 
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human PAH) forms a disulfide bridge to 373C and it seems possible that this covalent 
interaction reduces the dynamics of DictyoPAH compared to human PAH and also 
contributes to cofactor selectivity. This may partly explain the lack of conformational 
flexibility in DictyoPAH. Finally, iii) in close vicinity to the substrate binding pocket, 
DictyoPAH has a CC motif, where human PAH has an IC motif (positions 283, 284) 
(Paper I). We characterized a human PAH I283C mutant. It had strict PAH activity, 
but was devoid of positive cooperativity. It was tetrameric with similar stability as 
seen for the wild-type human PAH tetramer, but with lower affinity for both substrate 
and cofactor. Residue I283 in human PAH therefore seems important for the substrate 
induced activation. If it is replaced with a rigid residue like C the flexibility in this 
area adjacent to the active site is reduced and the substrate induced activation is 
prohibited, as positive cooperativity is lost. However, the I283C mutant is a tetramer. 
This indicates that there may be structural changes at the domain-domain interfaces 
so that the tetrameric conformation is preferred, but the active site changes associated 
with increased affinity are missing. Many other mutations have been shown to affect 
the positive cooperativity in human PAH, located throughout the enzyme, e.g. I65, 
E178, A300S (Erlandsen et al. 2004), C237 (Thorolfsson et al. 2003), P244, R261, 
A309, V388 (Pey et al. 2004), Y325 (Miranda et al. 2005), R408 and T427 (Bjorgo et 
al. 2001). All these residues are conserved in DictyoPAH (Paper I). Many of these 
residues appear to be essential for maintaining the structural integrity since they are 
involved in misfolding mutations associated with PKU 
(http://www.pahdb.mcgill.ca/).  
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4.4. The archetypical ACT domain (Paper III) 
The regulatory domain of the AAAH has been classified as an ACT domain. 
In this comparative review we consider three different ACT domains to the depth of 
their allosteric regulation in three different enzymes, namely D-3-phosphoglycerate 
dehydrogenase (3PGDH), the bifunctional chorismate-prephenate dehydrogenase (P-
protein), and PAH. L-Ser is the enzyme product of 3PGDH, which is allosterically 
feedback inhibited by L-Ser binding to the interface between two ACT domains. This 
ACT domain dimer with L-Ser bound has served as the paradigm for the domain 
function in ACT-domain containing proteins. The ACT regulatory domain in the P-
protein has also been found to coordinate L-Phe to a sequence motif (GALV-ESRP). 
The G from the GALV motif is found in most ACT domains (Aravind and Koonin 
1999) and the entire GALV – ESRP motif is found in the regulatory domain of PAH. 
The P-protein is involved in the two first enzymatic steps in the shikimate pathway, 
used by plants and microorganisms to biosynthesize L-Phe and L-Tyr (Herrmann and 
Weaver 1999). The P-proteins are allosterically feedback inhibited by L-Phe. Further, 
when L-Phe binds to the GALV-ESRP motif (with positive cooperativity) the protein 
shifts from being an active dimer to becoming a less active tetramer. The homology 
between the regulatory domains in the P-protein and in PAH is thus obvious. But 
while the dimeric regulatory ACT domain in the P-protein has been shown to bind L-
Phe  (Pohnert et al. 1999) and by so doing it fits the description of the archetypical 
ACT domain, the only available structure of the ACT domain in PAH (Kobe et al. 
1999) reveals that no contacts form between different ACT domains. Hence, there is 
no ACT domain dimer interface for L-Phe to bind to in mammalian PAH, and 
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experimental data suggests that L-Phe does not bind to any other site other than the 
active site (Thorolfsson et al. 2002). We reconstructed the phylogeny of the ACT 
domain in the P-protein and in the AAAHs. The phylogenetic tree shows that the 
AAAHs are a monophyletic group as compared to the ACT domain in the P-protein, 
which certainly may be the ancestor of all AAAH ACT domains, as previously 
suggested (Gjetting et al. 2001). The known function of the ACT domain in PAH 
today however indicates that the oligomeric state and the ligand binding functionality 
have changed compared to the P-protein, but the allosteric properties remain. It 
appears that the ACT domain itself is a highly flexible module (Paper III). 
 
4.5. Distant homologs of the ACT domain (Paper IV) 
The high sequence divergence, evolutionary mobility, and superfold topology 
of the ACT domain led us to believe that there may be more homologous 
relationships for this domain to be found. As we concluded in paper III, the ACT 
domain is a flexible module included in several proteins with various domain 
combinations, and although they are described as binding amino acids, this does not 
seem to be a strict requirement. We were especially interested in finding other 
functionalities that could be extrapolated to the AAAH. As we continued to search 
for the purpose of the ACT domain, it became evident that the ACT domain 
classification was inconsistent when comparing e.g. SCOP, CATH, and Pfam. 
Therefore, we decided to search for remote potential homologs of the ACT domain in 
the PDB, using the regulatory ACT domain in PAH as a query. Using a consensus 
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approach of FATCAT and SSAP led us to 18 potential ACT domains, many devoted 
to regulation. To avoid redundancy in our data, no pair had a sequence identity > 30 
%. Using the inverted SSAP scores as distances we built a tree of these results (Paper 
IV). This method clustered the known Pfam families well. PAH clustered next to 
another known ACT domain that is not binding amino acids, but Ni-ions. This cluster 
is located in between the main ACT domain cluster and a cluster of metallobinding 
domains. Yet another cluster away, we find the GlnB-like domains. These domains 
are also involved in amino acid metabolism, of e.g. L-His and L-Gln.  
A recent structure of prephenate dehydratase with L-Phe bound at the dimer 
interface (Tan et al. 2008), when superimposed to the structure of the regulatory 
domain and catalytic domain of PAH, reveals that the interface that is used by L-Phe 
to bind is not present in PAH, although the residues are conserved. The two binding-
sites in prephenate dehydratase are formed by the region GALV from one chain and 
ESRP from another chain, and vice versa. This leaves one the GALV binding-site too 
open as the catalytic domain is too distant to interact. The G-L motif is found in many 
ACT domains and in many of the potential ACT domain, which indicates that it may 
have a direct structural importance (Paper IV).  
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5. General discussion 
The AAAHs have provided an interesting system to study the interplay of 
protein structure and function. As phenylalanine hydroxylase evolved it has gone 
through various transitions. One gene encoding the catalytic domain in PAH is 
present in a seemingly random distribution of bacterial species. It is absent from 
archea and from some eukaryotic lineages, e.g. plants and fungi. As more protozoan 
genomes are being sequenced we notice that many of them have one copy of a PAH. 
Compared to bacterial PAH, the protozoan PAH has had two domain fusion events, 
aquiring an N-terminal domain as well as a C-terminal domain, consistent with 
domain fusion being more common than fission in the evolution of multidomain 
proteins (Kummerfeld and Teichmann 2005). As we proceed down the eukaryotic 
lineage into the metazoans, we note that all metazoans have at least three copies of 
the ancestral PAH gene. This is in accordance with the extensive radiation resulting 
in major gene duplications in early metazoan evolution (Lundin 1999). By 
experimentally characterizing DictyoPAH we can confirm that PAH was the original 
function. This means that two gene copies have been subject to neofunctionalization, 
TH and TPH. For TH a forward grade evolution as part of pathway evolution can be 
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depicted since its substrate is the product of PAH. The pathway in which PAH and 
TH are found, also include dopamine and adrenaline production and is highly 
important for various neurological process. TPH is found in a parallel pathway 
leading to e.g. serotonin production. Therefore, the evolution of the enzyme family 
from one PAH to a family of aromatic amino acid hydroxlases involved in various 
neurotransmitter production pathways were likely very important for the evolution of 
the animal kingdom. The triplication (or more) of PAH in early metazoans, was later 
followed by at least one round of genome duplication in the chordates to vertebrate 
transition (McLysaght et al. 2002). Initially, this ought to have meant at least 6 
AAAH genes, but in the eutherian mammalian lineage two genes were 
pseudogenized as there are 4 AAAH genes found in their genomes today. An 
additional copy of TPH was added to the AAAH family in eutherian mammals as 
compared to invertebrates. This last genome duplication also resulted in a division of 
the AAAH genes onto two chromosomes, with PAH and TPH on one and TH and 
TPH on the other. Other vertebrates may have additional copies of the AAAH genes 
as a result of the genome duplication mentioned above or by later lineage specific 
genome duplications. In e.g. chicken, we noted that it had kept an additional TH 
gene, since it is located on the same chromosome as PAH and one TPH. This is 
similar to the chromosomal location of the three AAAH genes in non-vertebrate 
metazoans. One interesting feature of DictyoPAH is its clear preference for its species 
specific biopterin cofactor (Paper I). D. discoideum is one of seemingly few 
protozans that can synthesis a close analog of biopterin, using the same pathway as 
higher eukaryotes (Werner-Felmayer et al. 2002). Some bacteria, e.g. Clorobium 
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tepidum, has the enzymes needed for biopterin synthesis, while most bacteria cannot 
synthesize biopterin (Supangat et al. 2008). Interestingly, the bacterial biopterin is yet 
another conformation of the biopterin found in higher eukaryotes (Supangat et al. 
2008).  
The domains that were added to the catalytic domain sometime in the early 
eukaryotic lineage added regulatory properties to the enzyme. The N-terminal domain 
is an ACT domain, which are often found in allosterically regulated metabolic 
enzymes, while the C-terminal domain has two structural motifs involved in the 
oligomerization of the enzymes. TH and TPH are functional as homotetramers. 
Mammalian PAH is sophistically regulated by its substrate, cofactor, and 
phosphorylation, all together altering the equilibrium between a low-affinity and low-
activity state to a high-affinity and high-activity state. This allosterically controlled 
regulation has not been detected for TH and TPH. Human PAH is the malfunctioning 
enzyme in PKU. More than 500 PKU causing mutations have been found 
(http://www.pahdb.mcgill.ca/). In a recent study of 10 PKU mutations located 
through-out the PAH sequences, several were found to impact the folding of the 
regulatory domain (Gersting et al. 2008). Our investigation of the allostery in PAH 
led us to the important domain junction of the regulatory and oligomerization domain 
from one subunit to the catalytic domain of the other subunit (Paper II), similar to 
another study by Thorolfsson et al (Thorolfsson et al. 2003). In addition we note a 
couple of radical amino acid substitution changes in the immediate substrate binding 
pocket that could account for stabilizing the high-affinity and high-activity state in 
nematode PAH, e.g. G272H and M276K (Paper II). Similarly, we note that also 
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DictyoPAH has two additional Cys residues lining the active site, e.g. I283C and 
I324C (Paper I). When the Dictyostelium discoideum specific biopterin cofactor is 
used, this PAH has high affinity for L-Phe (Paper I). These PAH are all devoid of the 
positive cooperativity seen in mammalian PAH. This indicates that the acquisition of 
a dynamic binding site is coupled to the acquisition of allostery, similar to what is 
seen for the allosterically activated PAH from the cold-adapted bacterium Colwellia 
psychrerythraea (Leiros et al. 2007).  
One of the conformational changes that we note between the low-affinity and 
low-activity models of human PAH seems to originate in the substrate binding pocket 
and lead over to the adjacent regulatory domain. Thus the human enzyme is 
characterized by a high mobility abd a large number of hinges (Stokka et al. 2004). 
Further, both the N-terminal and the C-terminal have been shown to be very flexible 
and susceptible to degradation, even for some PKU associated mutations that are not 
located in the N-terminal regulatory domain itself (Gersting et al. 2008). 
PKU is today regarded as a misfolding disease with many destabilizing 
mutations as the main pathogenic mechanism (Pey et al. 2007). For several PKU 
mutations treatment with the biopterin cofactor can reduce the L-Phe concentration by 
20-30 % depending on the severity of the mutation  ((Fiege and Blau 2007) and refs 
therein). The mechanism for the rescued PAH activity may relay in a chaperone-like 
effect of biopterin that can stablize PAH (Scavelli et al. 2005) and also prevent its 
degradation (Erlandsen et al. 2004). 
The regulatory domains of the different AAAH have highly divergent 
sequences. This is in accordance with its superfold topology. However, the 
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oligomeric state of the ACT domain has changed compared to other known ACT 
domains (Paper III and IV). The ACT domains are found in various combinations, 
forming dimers and tetramers face to face or side by side (Paper IV). In most cases 
ACT domains interact with other ACT domains, but this is not the case for the ACT 
domain in PAH.  Most known ACT domains bind various amino acids, which is 
logical given their involvement in amino acid metabolism. However, there is at least 
one example of an ACT domain that in addition to its amino acid binding specificity 
also has acquired an additional ligand binding site, namely aspartate kinase which 
binds L-Lys and S-adenosylmethionine (Curien et al. 2008). However, while L-Lys 
binds to the dimer interface between two ACT domains, S-adenosylmethionine binds 
to only one ACT domain (Curien et al. 2008). This adds proof of principle to the 
ACT domains versatility. Truncating the PAH enzyme to only include the ACT 
domain results in dimer formation and L-Phe binding at the interface (Gjetting et al. 
2001). This is likely the ancestral function of this domain, similar to what is seen for 
the P-protein (Paper III and IV). Perhaps the loss of the ACT domains ability to 
dimerize or form higher order structures as seen for other potential ACT domain 
homologs (Paper III) may be involved in rendering PAH highly susceptible to 
degradation for many PKU mutations. PAH has kept the L-Phe binding motif, but the 
structural constraints on how the domains assemble abolish its ancestral binding 
functionality (Paper IV). 
The ESRP part of the L-Phe binding motif in the P-protein is interacting with 
-helix 5 from the catalytic domain; an -helix which we predicted had important 
interactions for promoting the allosteric response (Paper II). In addition, the R in 
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ESRP is R68, has been found to be important for the allosteric response by its 
interactions to C237 (Thorolfsson et al. 2003). In paper II, we found these residues at 
a domain junction formed by the catalytic domain from one chain and the regulatory 
domain as well as the oligomerization domain from an adjacent chain. The difference 
between mammalian PAH and nematode PAH in our models is that nematode PAH 
can form more inter domain interactions in this area.  The regulatory domain has been 
shown to have large impact on human PAH stability and active site binding 
(Erlandsen et al. 2004; Gersting et al. 2008). Therefore, stabilizing the interactions 
between the regulatory domain and the rest of the enzyme may be beneficiary for 
correction of PKU mutations. Decreasing the pKa of the residues in the vicinity of 
R68 from the ESRP motif and the area around C237 in particular seems to be 
important for high activity ((Thorolfsson et al. 2003) and Paper II). This region may 
be a good target for stabilizing destabilized PAH in order to control the PKU 
phenotype by a small molecule drug approach.  
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6. Conclusions and future directions 
6.1. Conclusions 
Human PAH has become a fragile enzyme. This is highly noticeable given 
how frequent destabilizing mutations are. When comparing human PAH to PAH 
from both D. discoideum and C. elegans it becomes evident that human PAH must be 
more dynamic than these two, and it is indeed the case. The two additional Cys 
residues in close vicinity to both cofactor and substrate binding pockets in 
DictyoPAH are providing additional stability; one of these was confirmed to abolish 
cooperativity in human PAH as well. For PAH from C. elegans we have identified 
two strong candidates for making the active site less dynamic compared to human 
PAH. Both these residues, G272H and M276H, are located in close vicinity to the 
substrate binding pocket and probably involved in stabilizing the high-affinity and 
high-affinity state.  
The ACT domain is a functionally highly versatile domain, which structure is 
one of the most common in the current fold pool. As a superfold domain, the same 
secondary structure elements and connectivity can be achieved with highly divergent 
sequences. As structure is more conserved than sequence, we set out to identify more 
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potential homologs. Using only one of the current ACT domain, we idenitified 18 
new ACT domain candidates. Some of these where structural genomics targets with 
unknown function. By using a combination approach like this, insights to unknown 
domain functions can be gained. In addition, several non-redundant candidates were 
found from the same Pfam domains, the GlnB-like and heavy metal associated 
domains. There is probably a homologous connection between these domains and we 
are working on a way to show that (see future directions).  
The L-Phe binding motif found in the homologous P-protein ACT domain is 
conserved in PAH. In PAH, this motif can no longer bind L-Phe, due to the 
quaternary assembly of PAH. The catalytic domain is today surrounded by two 
different oligomerization domains, one at the N-terminus and one at the C-terminus. 
We have seen that the ACT domain at the N-terminus is frequently involved in 
dimerization (Paper III and IV), and the leucine zipper motif in the very C-terminus is 
frequently involved in forming tetramers. In the quarternary assembly of the full-
length multidomain AAAH protein, no contacts are formed between the different 
ACT domains. This may have resulted in the instability of the regulatory domain 
since it cannot interact with the other ACT domain from the adjacent subunit.  
The AAAH family does not seem to have evolved from an enzyme with broad 
substrate specificity, but from a PAH specific enzyme. This is also what we see in 
bacteria. However, it should be noted that PAH in bacteria may be the result of a 
horizontal gene transfer, but distribution in the bacterial kingdom is scattered.  
As we have shown for AAAH, the evolution of this multidomain protein in 
eukaryotes could be resolved with a suitable outgroup. This is probably the case for 
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many other eukaryotic multidomain proteins as well. By experimentally confirming 
the outgroup specificity and characteristics we have lots to learn about protein 
evolution of structure and function.  
In addition, we need to resolve the superfold domain ancestry in order to know 
how multidomain proteins really evolve, e.g. in TH the ACT domain has diverged 
beyond sequence recognition. If this and other domains are not classified in 
accordance to their homologs in various databases, then many studies based on 
various databases will be wrong in establishing various trends for e.g. multidomain 
evolution.  
Another application that can follow the understanding of superfold ancestry is 
protein structure prediction.  
 
6.2. Future directions 
(1) To get a better understanding of the different changes at the different 
interfaces, molecular dynamics simulations can be helpful. We have provided 
various interfaces and residues that are predicted to be important using 
bioinformatic statistical methods, electrostatic interaction energies, and 
structural models. Further, site directed mutagenesis can help test some of our 
hypothesis. 
(2)  Now is the time to start revisiting phylogenies of the multidomain proteins in 
order to get insights into their ancestral functions. The AAAHs are only one 
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of many other enzymes where copy number has increased in higher 
eukaryotes as compared to D. discoideum. Testing activities and substrate 
specificities will aid the understanding of domain and pathway evolution. This 
is crucial to our understanding of biology. 
(3) Ultimately, we would like to be able to prove that the known and potential 
ACT domains identified in this thesis are homologs, but how does one do 
that? There is no precise way to demonstrate homology between domains that 
have a sequence identity of 0-10 %, although the conserved features are 
unlikely to be the result of convergent evolution. We would like to mention 
that we have tried to prove homology using various ideas. Our first attempt 
was to identify the residues involved in forming the folding nucleus, believed 
to be essential for the folding process. There are at least two known sets of 
overlapping folding nucleons in ribosomal protein S6 (Olofsson et al. 2007). 
We found these patterns to be conserved throughout the set of our known and 
potential ACT domains, but this was not enough to claim homology. Further, 
we tried to use ancestral sequence reconstruction using a very basic idea that 
as the node of each known and potential ACT domain was reconstructed, the 
sequence identity and alignment score should increase; with the underlying 
hypothesis that if the domains are truly homologous their ancestors ought to 
show higher sequence similarity as present day sequences continue to evolve 
and diversify. This almost took us all the way, but we did not see 
improvement for all known ACT domains. Now, after giving up on this 
approach, I have come to realize that the fatal flaw was to not create 
 85 
homology models of the reconstructed sequences and to compare the models, 
not the sequences, to each other. Further, we could have extended the method 
to include more sequences since the top scoring sequence may not be an exact 
replica of the ancestral sequence. Collaboration with Prof. Lesley Collins at 
Massey University, New Zealand, has been initiated to continue developing 
the method of modeling ancestral sequences and structures in order to prove 
homology between superfold domains.  
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